{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:33:31Z","timestamp":1790969611235,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier","isbn-type":[{"value":"9780128177389","type":"print"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1016\/bs.pmbts.2019.01.005","type":"book-chapter","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T02:53:22Z","timestamp":1551840802000},"page":"265-276","source":"Crossref","is-referenced-by-count":52,"title":["Serum CA153 as biomarker for cancer and noncancer diseases"],"prefix":"10.1016","author":[{"given":"Xiulian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5517","key":"10.1016\/bs.pmbts.2019.01.005_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.01.005_bb0015","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hyb.1984.3.223","article-title":"Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors","volume":"3","author":"Kufe","year":"1984","journal-title":"Hybridoma"},{"issue":"4654","key":"10.1016\/bs.pmbts.2019.01.005_bb0020","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.6729450","article-title":"T and Tn, general carcinoma autoantigens","volume":"224","author":"Springer","year":"1984","journal-title":"Science"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.01.005_bb0025","first-page":"356","article-title":"Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions","volume":"28","author":"Szpak","year":"1984","journal-title":"Acta Cytol"},{"issue":"14","key":"10.1016\/bs.pmbts.2019.01.005_bb0030","first-page":"4107","article-title":"Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer","volume":"48","author":"Tondini","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.01.005_bb0035","first-page":"2379","article-title":"CA15-3 is present as a novel tumour marker in the sera of patients with breast cancer and other malignancies","volume":"12","author":"Gang","year":"1985","journal-title":"Gan To Kagaku Ryoho"},{"issue":"10","key":"10.1016\/bs.pmbts.2019.01.005_bb0040","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.1986.4.10.1542","article-title":"Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer","volume":"4","author":"Hayes","year":"1986","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.01.005_bb0045","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/bjc.1987.297","article-title":"Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer","volume":"56","author":"Sacks","year":"1987","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.005_bb0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF01806524","article-title":"Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases","volume":"13","author":"Colomer","year":"1989","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/bs.pmbts.2019.01.005_bb0055","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/bjs.1800760826","article-title":"CA15-3: its relationship to clinical stage and progression to metastatic disease in breast cancer","volume":"76","author":"Kerin","year":"1989","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.005_bb0060","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.1991.179","article-title":"The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases","volume":"63","author":"Gion","year":"1991","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.01.005_bb0065","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/1097-0142(19910801)68:3<574::AID-CNCR2820680322>3.0.CO;2-B","article-title":"The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen","volume":"68","author":"Safi","year":"1991","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/bs.pmbts.2019.01.005_bb0070","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1200\/JCO.1992.10.7.1057","article-title":"Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen","volume":"10","author":"Daly","year":"1992","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.005_bb0075","first-page":"210","article-title":"A prospective evaluation of CA15-3 in stage I carcinoma of the breast","volume":"180","author":"O'Hanlon","year":"1995","journal-title":"J Am Coll Surg"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.01.005_bb0080","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0959-8049(94)00447-1","article-title":"Tumour marker CA15-3: possible uses in the routine management of breast cancer","volume":"31A","author":"Tomlinson","year":"1995","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.005_bb0085","first-page":"630","article-title":"Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer","volume":"45","author":"Gion","year":"1999","journal-title":"Clin Chem"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.01.005_bb0090","first-page":"2834","article-title":"Structural analysis of the DF3 human breast carcinoma-associated protein","volume":"49","author":"Abe","year":"1989","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/bs.pmbts.2019.01.005_bb0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000056510","article-title":"Effect of desialylation on binding, affinity, and specificity of 56 monoclonal antibodies against MUC1 mucin","volume":"19","author":"Dai","year":"1998","journal-title":"Tumour Biol"},{"issue":"5","key":"10.1016\/bs.pmbts.2019.01.005_bb0100","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.4049\/jimmunol.135.5.3610","article-title":"Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas","volume":"135","author":"Sekine","year":"1985","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.01.005_bb0105","first-page":"786","article-title":"Complexity of MAM-6, an epithelial sialomucin associated with carcinomas","volume":"49","author":"Hilkens","year":"1989","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0110","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/1471-2407-12-600","article-title":"Mucin-1 and its relation to grade, stage and survival in ovarian carcinoma patients","volume":"12","author":"Engelstaedter","year":"2012","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0115","article-title":"Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy","volume":"9","author":"Riva","year":"2014","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/bs.pmbts.2019.01.005_bb0120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Sritama","year":"2014","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1309\/9R6673QEC06D86Y4","article-title":"Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study","volume":"122","author":"Lau","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.005_bb0130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0021-9258(19)85024-X","article-title":"Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Gal beta(1-4)GlcNAc beta(1-6) repeating units","volume":"264","author":"Hanisch","year":"1989","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0304-4165(99)00170-1","article-title":"Pathways of O -glycan biosynthesis in cancer cells","volume":"1473","author":"Brockhausen","year":"1999","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.005_bb0140","first-page":"1","article-title":"Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis","volume":"13","author":"Ola","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/bs.pmbts.2019.01.005_bb0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.talanta.2012.05.005","article-title":"Novel automated flow-based immunosensor for real-time measurement of the breast cancer biomarker CA15-3 in serum","volume":"97","author":"Darwish","year":"2012","journal-title":"Talanta"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0150","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s12291-012-0257-0","article-title":"Diagnostic role of tumour markers CEA, CA15-3, CA19-9 and CA125 in lung cancer","volume":"28","author":"Ghosh","year":"2013","journal-title":"Indian J Clin Biochem"},{"issue":"S6","key":"10.1016\/bs.pmbts.2019.01.005_bb0155","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/1097-0142(19920315)69:6+<1578::AID-CNCR2820691312>3.0.CO;2-K","article-title":"Molecular marker test standardization","volume":"69","author":"Koepke","year":"1992","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.01.005_bb0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF02966721","article-title":"Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer","volume":"10","author":"Nishimura","year":"2003","journal-title":"Breast Cancer"},{"issue":"33","key":"10.1016\/bs.pmbts.2019.01.005_bb0165","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/bs.pmbts.2019.01.005_bb0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1183\/09031936.93.01040341","article-title":"Diagnostic value of cancer antigen 15-3 (CA15-3) detected by monoclonal antibodies (115D8 and DF3) in exudative pleural effusions","volume":"1","author":"Shimokata","year":"1988","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.005_bb0175","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2340\/0001555574183187","article-title":"DF3 (CA15-3) antibody as a marker of cutaneous adnexal tumors","volume":"74","author":"Yasui","year":"1994","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/bs.pmbts.2019.01.005_bb0180","doi-asserted-by":"crossref","first-page":"8629712","DOI":"10.1155\/2017\/8629712","article-title":"A panel of CA19-9, Ca125, and Ca15-3 as the enhanced test for the differential diagnosis of the pancreatic lesion","volume":"2017","author":"Hogendorf","year":"2017","journal-title":"Dis Markers"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.01.005_bb0185","first-page":"260","article-title":"Value of combined detection of serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the diagnosis of gastric cancer","volume":"47","author":"Chen","year":"2017","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/bs.pmbts.2019.01.005_bb0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ijc.2910410813","article-title":"Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays","volume":"3","author":"Yedema","year":"1988","journal-title":"Int J Cancer Suppl"},{"issue":"23","key":"10.1016\/bs.pmbts.2019.01.005_bb0195","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","article-title":"CA 15-3: uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/bs.pmbts.2019.01.005_bb0200","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1470-2045(00)00227-8","article-title":"Elevation of CA15-3 caused by a benign tumour","volume":"2","author":"Ghnassia","year":"2001","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.01.005_bb0205","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1021\/ac902492c","article-title":"Enhanced gold nanoparticle based ELISA for a breast cancer biomarker","volume":"82","author":"Adriano","year":"2010","journal-title":"Anal Chem"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0210","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0958-1669(96)80096-6","article-title":"Advances in immunoassay technology","volume":"7","author":"Self","year":"1996","journal-title":"Curr Opin Biotechnol"},{"issue":"1\u20132","key":"10.1016\/bs.pmbts.2019.01.005_bb0215","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0022-1759(92)90061-W","article-title":"Enzyme immunoassay techniques. An overview","volume":"150","author":"Porstmann","year":"1992","journal-title":"J Immunol Methods"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000056500","article-title":"Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif., November 17\u201323, 1996","volume":"19","author":"Price","year":"1998","journal-title":"Tumor Biol"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0225","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/clinchem\/42.1.28","article-title":"Multicenter evaluation of the Abbott IMx CA 15-3 assay","volume":"42","author":"van Kamp","year":"1996","journal-title":"Clin Chem"},{"key":"10.1016\/bs.pmbts.2019.01.005_bb0230","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bios.2018.08.047","article-title":"A highly sensitive and reliable detection of CA15-3 in patient plasma with electrochemical biosensor labeled with magnetic beads","volume":"122","author":"Akbari Nakhjavani","year":"2018","journal-title":"Biosens Bioelectron"},{"issue":"23","key":"10.1016\/bs.pmbts.2019.01.005_bb0235","doi-asserted-by":"crossref","first-page":"35478","DOI":"10.18632\/oncotarget.8155","article-title":"Hallmarks of glycosylation in cancer","volume":"7","author":"Munkley","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/bs.pmbts.2019.01.005_bb0240","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10719-012-9437-7","article-title":"Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity","volume":"30","author":"Lavrsen","year":"2013","journal-title":"Glycoconj J"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0245","first-page":"145","article-title":"Use of CA15-3 for screening breast cancer: an antibody-lectin sandwich assay for detecting glycosylation of CA15-3 in sera","volume":"40","author":"Choi","year":"2018","journal-title":"Oncol Rep"},{"issue":"11","key":"10.1016\/bs.pmbts.2019.01.005_bb0250","doi-asserted-by":"crossref","first-page":"53R","DOI":"10.1093\/glycob\/cwh122","article-title":"History of lectins: from hemagglutinins to biological recognition molecules","volume":"14","author":"Nathan","year":"2004","journal-title":"Glycobiology"},{"issue":"1","key":"10.1016\/bs.pmbts.2019.01.005_bb0255","first-page":"145","article-title":"Use of CA153 for screening breast cancer: an antibody-lectin sandwich assay for detecting glycosylation of CA153 in sera","volume":"40","author":"Choi","year":"2018","journal-title":"Oncol Rep"}],"container-title":["Progress in Molecular Biology and Translational Science","Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187711731930016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187711731930016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T05:13:23Z","timestamp":1694668403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187711731930016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9780128177389"],"references-count":50,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2019.01.005","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2019]]}}}